ProtoKinetix

ProtoKinetix Change in Working Capital

The Change in Working Capital of ProtoKinetix (PKTX) as of Nov 19, 2026 is 206,981.00 USD. In the previous year, Change in Working Capital was 82,851.00 USD — a change of 149.82% (higher).

Change in Working Capital

206,981.00USD

YoY

149.82%

Last updated:

Change in Working Capital of ProtoKinetix is 2025 206,981.00 USD. Change in Working Capital of ProtoKinetix was 2024 82,851.00 USD. It decreases by 149.82% higher compared to the previous year.

The ProtoKinetix Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
110,771.00 USD
Jan 1, 2019
-51,080.00 USD
Jan 1, 2020
19,439.00 USD
Jan 1, 2021
23,364.00 USD
Jan 1, 2022
-26,793.00 USD
Jan 1, 2023
-8,768.00 USD
Jan 1, 2024
82,851.00 USD
Jan 1, 2025
206,981.00 USD
The ProtoKinetix Change in Working Capital history
YEARChange in Working CapitalYoY
206,981.00USD+149.82%
82,851.00USD-1,044.92%
-8,768.00USD-67.28%
-26,793.00USD-214.68%
23,364.00USD+20.19%
19,439.00USD-138.06%
-51,080.00USD-146.11%
110,771.00USD-1,803.91%
-6,501.00USD-90.10%
-65,688.00USD+210.49%
-21,156.00USD-115.36%
137,750.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Change in Working Capital of ProtoKinetix is 206,981.00 USD in 2025.

Change in Working Capital of ProtoKinetix changed from 82,851.00 USD to 206,981.00 USD, representing a 149.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ProtoKinetix

All Key Metrics — ProtoKinetix